BioCentury | Feb 7, 2011
Product Development

Obesity Reset

...SGLT2) inhibitor Ph II NeuroSearch A/S (CSE:NEUR) Tesofensine (NS2330) Triple monoamine reuptake inhibitor Ph II Obecure Ltd....
BioCentury | Jun 22, 2009
Clinical News

Histalean: Phase Ib data

...placebo (1.2 vs. 1.9 kg, p<0.05). Eli Lilly and Co. (NYSE:LLY, Indianapolis, Ind.) markets Zyprexa. Obecure Ltd....
BioCentury | Jan 26, 2009
Clinical News

Histalean: Completed Phase II enrollment

...Phase IIb (BET-207) trial evaluating 48 or 96 mg/day of oral Histalean for 12 weeks. Obecure Ltd....
BioCentury | Sep 15, 2008
Clinical News

Histalean: Phase II started

...to evaluate 48 or 96 mg/day Histalean for 12 weeks in 180 obese, premenopausal women. Obecure Ltd....
BioCentury | Sep 3, 2007
Clinical News

Histalean: Phase II data

...significant - the Histalean patients lost 2.61 kg compared with 0.4 kg for placebo (p=0.003). Obecure Ltd....
BioCentury | Aug 31, 2007
Clinical News

Obecure reports obesity data

Obecure (Ramat Gan, Israel) said all three doses of Histalean (16, 32 and 48 mg/day) failed to show statistically significant differences in weight loss vs. placebo in a Phase II trial to treat obesity. A...
BioCentury | Jul 2, 2007
Clinical News

OBE101: Phase II completed

...comparing 16, 32 and 48 mg doses of twice-daily OBE101 vs. placebo for 12 weeks. Obecure Ltd....
BioCentury | May 21, 2007
Clinical News

OBE101: Phase II started

...OBE101 in combination with Zocor simvastatin from Merck & Co. Inc. (MRK, Whitehouse Station, N.J.). Obecure Ltd....
BioCentury | Apr 16, 2007
Clinical News

OBE101: Completed Phase II enrollment

...receive 16, 32 or 48 mg doses of twice-daily OBE-101 or placebo for 12 weeks. Obecure Ltd....
BioCentury | Mar 26, 2007
Product Development

Targeting obesity

...number of compounds are suppressing appetite by affecting neurotransmitters dopamine, noradrenaline, serotonin and histamine, including Obecure's...
Items per page:
1 - 10 of 14
BioCentury | Feb 7, 2011
Product Development

Obesity Reset

...SGLT2) inhibitor Ph II NeuroSearch A/S (CSE:NEUR) Tesofensine (NS2330) Triple monoamine reuptake inhibitor Ph II Obecure Ltd....
BioCentury | Jun 22, 2009
Clinical News

Histalean: Phase Ib data

...placebo (1.2 vs. 1.9 kg, p<0.05). Eli Lilly and Co. (NYSE:LLY, Indianapolis, Ind.) markets Zyprexa. Obecure Ltd....
BioCentury | Jan 26, 2009
Clinical News

Histalean: Completed Phase II enrollment

...Phase IIb (BET-207) trial evaluating 48 or 96 mg/day of oral Histalean for 12 weeks. Obecure Ltd....
BioCentury | Sep 15, 2008
Clinical News

Histalean: Phase II started

...to evaluate 48 or 96 mg/day Histalean for 12 weeks in 180 obese, premenopausal women. Obecure Ltd....
BioCentury | Sep 3, 2007
Clinical News

Histalean: Phase II data

...significant - the Histalean patients lost 2.61 kg compared with 0.4 kg for placebo (p=0.003). Obecure Ltd....
BioCentury | Aug 31, 2007
Clinical News

Obecure reports obesity data

Obecure (Ramat Gan, Israel) said all three doses of Histalean (16, 32 and 48 mg/day) failed to show statistically significant differences in weight loss vs. placebo in a Phase II trial to treat obesity. A...
BioCentury | Jul 2, 2007
Clinical News

OBE101: Phase II completed

...comparing 16, 32 and 48 mg doses of twice-daily OBE101 vs. placebo for 12 weeks. Obecure Ltd....
BioCentury | May 21, 2007
Clinical News

OBE101: Phase II started

...OBE101 in combination with Zocor simvastatin from Merck & Co. Inc. (MRK, Whitehouse Station, N.J.). Obecure Ltd....
BioCentury | Apr 16, 2007
Clinical News

OBE101: Completed Phase II enrollment

...receive 16, 32 or 48 mg doses of twice-daily OBE-101 or placebo for 12 weeks. Obecure Ltd....
BioCentury | Mar 26, 2007
Product Development

Targeting obesity

...number of compounds are suppressing appetite by affecting neurotransmitters dopamine, noradrenaline, serotonin and histamine, including Obecure's...
Items per page:
1 - 10 of 14